Neutralizing antibodies against interferon-beta

Therapeutic Advances in Neurological Disorders

Volumn 1, Issue 2, 2008, Pages 125-141

  Soelberg Sorensen, Per ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Anti interferon antibodies; Binding antibodies; Bioactivity; Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

EID: 84993748625     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285608095144     Document Type: Review

References (106)

1. Bansil, S., Singhal, B.S., Ahuja, G.K., Ladiwala, U., Behari, M., Friede, R. et al. (1996) Comparison between multiple sclerosis in India and the United States: a case-control study. Neurology 46: 385-387.
2. Barbosa, M.D., Vielmetter, J., Chu, S., Smith, D.D. and Jacinto, J. (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 118: 42-50.
3. Bellomi, F., Muto, A., Palmieri, G., Focaccetti, C., Dianzani, C., Mattei, M. et al. (2007) Immunogenicity comparison of interferon beta-1a preparations using the BALB / c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiol 30: 241-246.
4. Bellomi, F., Scagnolari, C., Tomassini, V., Gasperini, C., Paolillo, A., Pozzilli, C. et al. (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215: 3-8.
5. Bendtzen, K. (2003) Anti-IFN BAb and NAb antibodies: a mini review. Neurology 61(suppl 5): S6-S10.
6. Bertolotto, A., Gilli, F., Sala, A., Capobianco, M., Malucchi, S., Milano, E. et al. (2003) Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60: 634-639.
7. Bertolotto, A., Sala, A., Caldano, M., Capobianco, M., Malucchi, S., Marnetto, F. et al. (2007) Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 321: 19-31.
8. Boz, C., Oger, J., Gibbs, E. and Grossberg, S.E. (2007) Reduced effectiveness of long-term interferon{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 13: 1127-1137.
9. Calabresi, P.A., Wilterdink, J.L., Rogg, J.M., Mills, P., Webb, A. and Whartenby, K.A. (2002) An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58: 314-317.
10. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.J., Martin-Dupont, P. et al. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475.
11. Chadha, K., Weinstock-Guttman, B., Zivadinov, R., Bhasi, K., Muhitch, J., Feichter, J. et al. (2006) Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol 63: 1579-1584.
12. Chiu, A.W., Ehrmantraut, M., Richert, N.D., Ikonomidou, V.N., Pellegrini, S., McFarland, H.F. et al. (2007) A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging. Clin Exp Immunol 150: 61-67.
13. Clanet, M., Radue, E.W., Kappos, L., Hartung, H.P., Hohlfeld, R., Sandberg-Wollheim, M. et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59: 1507-1517.
14. Cook, S.D., Quinless, J.R., Jotkowitz, A. and Beaton, P. (2001) Serum IFN neutralizing antibodies and neopterin levels in a cross- section of MS patients. Neurology 57: 1080-1084.
15. Deisenhammer, F., Mayringer, I., Harvey, J., Dilitz, E., Gasse, T., Stadlbauer, D. et al. (2000) A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 54: 2055-2060.
16. Deisenhammer, F., Reindl, M., Harvey, J., Gasse, T., Dilitz, E. and Berger, T. (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52: 1239-1243.
17. Duquette, P., Girard, M., Despault, L., Dubois, R., Knobler, R.L., Lublin, F.D. et al. (1993) Interferon Beta-1B Is Effective in Relapsing-Remitting Multiple-Sclerosis - Clinical-Results of A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Neurology 43: 655-661.
18. Duquette, P., Girard, M., Dubois, R., Kobler, R.L., Lublin, F., Kelley, L. et al. (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology 47: 889-894.
19. Durelli, L., Ricci, A., Bergui, P., Pipieri, A., Cucci, A., Festa, B. et al. (2006). High-dose (375 mcg) interferon beta-1b treatment of multiple sclerosis and neutralizing antibodies. Long-term follow-up. J Neurol 253(Suppl. 2): 100.
20. Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A. et al. (2002) Every-other-day interferon beta-1b vs once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359: 1453-1460.
21. European Study Group on interferon beta-1b in secondary progressive M.S. (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-1497.
22. Farrell, R., Kapoor, R., Leary, S.M., Rudge, P., Thompson, A.J., Miller, D.H. et al. (2007) Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 14: 212-218.
23. Farrell, R.A. and Giovannoni, G. (2007) Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis. MultScler 13: 567-577.
24. Fernandez, O., Guerrero, M., Mayorga, C., Munoz, L., Lean, A., Luque, G. et al. (2002) Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J Neurol 249: 1058-1062.
25. Files, J.G., Hargrove, D., Delute, L. and Cantillon, M. (2007) Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res 27: 637-642.
26. Fox, E.J., Vartanian, T.K. and Zamvil, S.S. (2007) The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 13: 355-362.
27. Francis, G.S., Rice, G.P. and Alsop, J.C. (2005) Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65: 48-55.
28. Frank, J.A., Richert, N., Bash, C., Stone, L., Calabresi, P.A., Lewis, B. et al. (2004) Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 62: 719-725.
29. Freedman, M.S., Francis, G.S., Sanders, E.A., Rice, G.P., O'Connor, P., Comi, G. et al. (2005) Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11: 41-45.
30. Freeman, J.A., Langdon, D.W., Hobart, J.C. and Thompson, A.J. (1997) The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 42: 236-244.
31. Friedman, J.E., Zabriskie, J. and Bourganskaia, E. (1996) A pilot study of pentoxifylline in multiple sclerosis. Arch Neurol 53: 956-957.
32. Garg, N., Weinstock-Guttman, B., Bhasi, K., Locke, J. and Ramanathan, M. (2007) An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis. Mult Scler 13: 895-899.
33. Gibbs, E., Tremlett, H., Ball, N. and Hashimoto, S. (2008) Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta. Eur J Neurol 15: e4.
34. Gilli, F., Hoffmann, F., Sala, A., Marnetto, F., Caldano, M., Kappos, L. et al. (2006 a) Qualitative and quantitative analysis of antibody response against IFNbeta in patients with Multiple Sclerosis. Multiple Sclerosis 12 (6): 738-746.
35. Gilli, F., Marnetto, F., Caldano, M., Sala, A., Malucchi, S., Capobianco, M. et al. (2006 b) Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 12: 47-57.
36. Gilli, F., Marnetto, F., Caldano, M., Sala, A., Malucchi, S., Di, S.A. et al. (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158: 195-203.
37. Gilli, F., Marnetto, F., Caldano, M., Valentino, P., Granieri, L., Di, S.A. et al. (2007) Anti-interferon-beta neutralizing activity is not entirely mediated by antibodies. J Neuroimmunol 192: 198-205.
38. Giovannoni, G., Barbarash, O., Casset-Semanaz, F., Jaber, A., King, J., Metz, L. et al. (2007) Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther 29: 1128-1145.
39. Giovannoni, G. and Goodman, A. (2005) Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 65: 6-8.
40. Gneiss, C., Reindl, M., Berger, T., Lutterotti, A., Ehling, R., Egg, R. et al. (2004 a) Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 24: 283-290.
41. Gneiss, C., Reindl, M., Lutterotti, A., Ehling, R., Egg, R., Khalil, M. et al. (2004 b) Interferon-beta: the neutralizing antibody (NAb) titer predicts reversion to NAb negativity. Mult Scler 10: 507-510.
42. Gneiss, C., Tripp, P., Ehling, R., Khalil, M., Lutterotti, A., Egg, R. et al. (2006 a) Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroimmunol 174: 174-179.
43. Gneiss, C., Tripp, P., Reichartseder, F., Egg, R., Ehling, R., Lutterotti, A. et al. (2006 b) Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 12: 731-737.
44. Goodin, D.S., Frohman, E.M., Hurwitz, B., O'Connor, P.W., Oger, J.J., Reder, A.T. et al. (2007 a) Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68: 977-984.
45. Goodin, D.S., Hurwitz, B. and Noronha, A. (2007 b) Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 35: 173-187.
46. Grossberg, S.E., Kawade, Y., Kohase, M. and Klein, J.P. (2001 a) The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21: 743-755.
47. Grossberg, S.E., Kawade, Y., Kohase, M., Yokoyama, H. and Finter, N. (2001 b) The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21: 729-742.
48. Herndon, R.M., Rudick, R.A., Munschauer, F.E., III, Mass, M.K., Salazar, A.M., Coats, M.E. et al. (2005) Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 11: 409-419.
49. Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898-904.
50. Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-294.
51. Kappos, L., Clanet, M., Sandberg-Wollheim, M., Radue, E.W., Hartung, H.P., Hohlfeld, R. et al. (2005) Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65: 40-47.
52. Kob, M., Harvey, J., Schautzer, F., Kascha, S., Bibl, D., Egg, R. et al. (2003) A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta. Mult Scler 9: 32-35.
53. Malucchi, S., Capobianco, M., Gilli, F., Marnetto, F., Caldano, M., Sala, A. et al. (2005) Fate of multiple sclerosis patients positive for neutralizing antibodies towards interferon beta shifted to alternative treatments. Neurol Sci 26(suppl 4): S213-S214.
54. Malucchi, S., Sala, A., Gilli, F., Bottero, R., Di, S.A., Capobianco, M. et al. (2004) Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62: 2031-2037.
55. Massart, C., de Gibassier J.S.J., Debouverie, M., Moreau, T., Pelletier, J. et al. (2008) Determination of interferon beta neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a cytopathic effect assay. Clin Chim Acta 391: 98-101.
56. McKay, F., Schibeci, S., Heard, R., Stewart, G. and Booth, D. (2006) Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J Immunol Methods 310: 20-29.
57. Millonig, A., Gneiss, C., Reindl, M., Berger, T. and Deisenhammer, F. (2007) High dose intravenous interferon beta in patients with neutralizing antibodies (HINABS) - a pilot study. Mult Scler 13: S269.
58. Minagara, A. and Murray, T.J. (2008) Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. Curr Med Res Opin 24: 1049-1055.
59. Namaka, M., Pollitt-Smith, M., Gupta, A., Klowak, M., Vasconcelos, M., Turcotte, D. et al. (2006) The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin 22: 223-239.
60. Noronha, A. (2007) Neutralizing antibodies to interferon. Neurology 68: S16-S22.
61. Oger, J. and Gibbs, E. (2006) Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis? Nat Clin Pract Neurol 2: 76-77.
62. Pachner, A., Narayan, K. and Pak ( 2006) Multiplex analysis of expression of three IFN-beta-induced genes in antibody-positive MS patients. Neurology 66 (3): 444-446.
63. Pachner, A., Narayan, K., Price, N., Hurd, M. and Dail, D. (2003 a) MxA Gene Expression Analysis as an Interferon-beta Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity. Mol Diagn 7: 17-25.
64. Pachner, A.R., Bertolotto, A. and Deisenhammer, F. (2003 b) Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 61: S24-S26.
65. Pachner, A.R., Dail, D., Pak, E. and Narayan, K. (2005) The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 166: 180-188.
66. Panitch, H., Goodin, D.S., Francis, G., Chang, P., Coyle, P.K., O'Connor, P. et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496-1506.
67. Panitch, H., Miller, A., Paty, D. and Weinshenker, B. (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63: 1788-1795.
68. Paty, D.W. and Li, D.K. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS / MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43: 662-667.
69. Perini, P., Facchinetti, A., Bulian, P., Massaro, A.R., Pascalis, D.D., Bertolotto, A. et al. (2001) Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12: 56-61.
70. Petersen, B., Bendtzen, K., Koch-Henriksen, N., Ravnborg, M., Ross, C. and Sorensen, P.S. (2006) Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 12: 247-252.
71. Petkau, A.J., White, R.A., Ebers, G.C., Reder, A.T., Sibley, W.A., Lublin, F.D. et al. (2004) Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 10: 126-138.
72. Polman, C., Kappos, L., White, R., Dahlke, F., Beckmann, K., Pozzilli, C. et al. (2003 b) Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60: 37-43.
73. Polman, C., Kappos, L., White, R., Dahlke, F., Beckmann, K., Pozzilli, C. et al. (2003 a) Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60: 37-43.
74. Polman, C.H., Kappos, L., Petkau, J. and Thompson, A. (2003 c) neutralizing antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 74: 1162-1163.
75. Pozzilli, C., Antonini, G., Bagnato, F., Mainero, C., Tomassini, V., Onesti, E. et al. (2002) Monthly corticosteroids decrease neutralizing antibodies to IFNbeta 1 b: a randomized trial in multiple sclerosis. J Neurol 249: 50-56.
76. Prince, H.E., Lape-Nixon, M., Audette, C. and Van, H.K. (2007) Identification of interferon-beta antibodies in a reference laboratory setting: Findings for 1144 consecutive sera. J Neuroimmunol 190: 165-169.
77. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group ( 1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing / remitting multiple sclerosis. Lancet 352: 1498-1504.
78. PRISMS Study Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56: 1628-1636.
79. Pungor Jr, E., Files, J.G., Gabe, J.D., Do, L.T., Foley, W.P., Gray, J.L. et al. (1998) A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 18: 1025-1030.
80. Rice, G.P., Paszner, B., Oger, J., Lesaux, J., Paty, D. and Ebers, G. (1999) The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52: 1277-1279.
81. Ross, C., Svenson, M., Clemmesen, K.M., Sorensen, P.S., Koch-Henriksen, N. and Bendtzen, K. (2006) Measuring and evaluating interferon-beta-induced antibodies in patients with multiple sclerosis. Mult Scler 12: 39-46.
82. Ross, C., Clemmesen, K.M., Svenson, M., Sorensen, P.S., Koch-Henriksen, N., Skovgaard, G.L. et al. (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48: 706-712.
83. Rudick, R.A. and Goodkin, D.E. (1999) Multiple sclerosis therapeutics, Martin Dunitz: London.
84. Rudick, R.A., Simonian, N.A., Alam, J.A., Campion, M., Scaramucci, J.O., Jones, W. et al. (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50: 1266-1272.
85. Runkel, L., Meier, W., Pepinsky, R.B., Karpusas, M., Whitty, A., Kimball, K. et al. (1998) Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15: 641-649.
86. Santos, R., Weinstock-Guttman, B., Tamano-Blanco, M., Badgett, D., Zivadinov, R., Justinger, T. et al. (2006) Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 176: 125-133.
87. Scagnolari, C., Duda, P., Bagnato, F., De, V.G., Alberelli, A., Lavolpe, V. et al. (2007) Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol 254: 597-604.
88. Schellekens, H. (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1: 457-462.
89. Schellekens, H. (2003) The immunogenicity of biopharmaceuticals. Neurology 61: S11-S12.
90. Sellebjerg, F., Datta, P., Larsen, J., Rieneck, K., Alsing, I., Oturai, A. et al. (2008) Gene expression analysis of interferon-{beta} treatment in multiple sclerosis. Mult Scler 14: 615-621.
91. Smith, D.R., Balashov, K.E., Hafler, D.A., Khoury, S.J. and Weiner, H.L. (1997) Immune deviation following pulse cyclophosphamide / methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 42: 313-318.
92. Sominanda, A., Hillert, J. and Fogdell-Hahn, A. (2008) In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralizing antibodies is titer-dependent. J Neurol Neurosurg Psychiatry 79: 57-62.
93. Sominanda, A., Rot, U., Suoniemi, M., Deisenhammer, F., Hillert, J. and Fogdell-Hahn, A. (2007) Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13: 208-214.
94. Sorensen, P.S., Koch-Henriksen, N., Flachs, E.M. and Bendtzen, K. (2008) Is treatment effect of IFN-beta restored after disappearance of neutralizing antibodies? Mult Scler 14: 837-842.
95. Sorensen, P.S. and Bertolotto, A. (2007) Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 69 (15): 1552.
96. Sorensen, P.S., Deisenhammer, F., Duda, P., Hohlfeld, R., Myhr, K.M., Palace, J. et al. (2005 a) Guidelines on use of anti-interferon-beta antibody measurements in multiple sclerosis - Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12: 817-827.
97. Sorensen, P.S., Koch-Henriksen, N. and Bendtzen, K. (2007) Are ex vivo neutralizing antibodies against IFN-{beta} always detrimental to therapeutic efficacy in multiple sclerosis? Mult Scler 13: 616-621.
98. Sorensen, P.S., Koch-Henriksen, N., Ross, C., Clemmesen, K.M. and Bendtzen, K. (2005 b) Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65: 33-39.
99. Sorensen, P.S., Ross, C., Clemmesen, K.M., Bendtzen, K., Frederiksen, J.L., Jensen, K. et al. (2003) Clinical importance of neutralizing antibodies against interferon beta in patients with relapsingremitting multiple sclerosis. Lancet 362: 1184-1191.
100. Sorensen, P.S., Tscherning, T., Mathiesen, H.K., Langkilde, A.R., Ross, C., Ravnborg, M. et al. (2006) Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 67: 1681-1683.
101. Spectrims (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56: 1496-1504.
102. Thompson, A.J., Miller, D., Youl, B., MacManus, D., Moore, S., Kingsley, D. et al. (1992) Serial gadolinium-enhanced MRI in relapsing / remitting multiple sclerosis of varying disease duration. Neurology 42: 60-63.
103. Tomassini, V., Paolillo, A., Russo, P., Giugni, E., Prosperini, L., Gasperini, C. et al. (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253: 287-293.
104. Wandinger, K.P., Lunemann, J.D., Wengert, O., Bellmann-Strobl, J., Aktas, O., Weber, A. et al. (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361: 2036-2043.
105. Weinstock-Guttman, B., Badgett, D., Patrick, K., Hartrich, L., Santos, R., Hall, D. et al. (2003) Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 171: 2694-2702.
106. Wood, N.W., Sawcer, S.J., Kellar Wood, H.F., Holmans, P., Clayton, D., Robertson, N. et al. (1995) The T-cell receptor beta locus and susceptibility to multiple sclerosis. Neurology 45: 1859-1863.